The Novo Nordisk Foundation (NNF) is funding a major new R&D initiative in the area of respiratory infections, with up to DKK 1.8 billion ($260 million) earmarked for
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<